196 related articles for article (PubMed ID: 25960092)
1. Assessing 15 proposals for promoting innovation and access to medicines globally.
Hoffman SJ; So K;
Ann Glob Health; 2014; 80(6):432-43. PubMed ID: 25960092
[TBL] [Abstract][Full Text] [Related]
2. Privatized Pharmaceutical Innovation vs Access to Essential Medicines: A Global Framework for Equitable Sharing of Benefits.
Burci GL; Gostin LO
JAMA; 2017 Feb; 317(5):473-474. PubMed ID: 28170485
[No Abstract] [Full Text] [Related]
3. New models for pharmaceutical innovation in low-income countries.
Ardal C; Iversen JH; Myhr K
Tidsskr Nor Laegeforen; 2011 Oct; 131(20):2016-8. PubMed ID: 22016131
[No Abstract] [Full Text] [Related]
4. The Health Impact Fund: a potential solution to inequity in global drug access.
Banerjee A; Pogge T
Indian J Med Ethics; 2010; 7(4):240-3. PubMed ID: 22106579
[TBL] [Abstract][Full Text] [Related]
5. Cautionary Notes on a Global Tiered Pricing Framework for Medicines.
Williams OD; Ooms G; Hill PS
Am J Public Health; 2015 Jul; 105(7):1290-3. PubMed ID: 25973806
[TBL] [Abstract][Full Text] [Related]
6. The roles of patents and research and development incentives in biopharmaceutical innovation.
Grabowski HG; DiMasi JA; Long G
Health Aff (Millwood); 2015 Feb; 34(2):302-10. PubMed ID: 25646111
[TBL] [Abstract][Full Text] [Related]
7. In which developing countries are patents on essential medicines being filed?
Beall RF; Blanchet R; Attaran A
Global Health; 2017 Jun; 13(1):38. PubMed ID: 28651631
[TBL] [Abstract][Full Text] [Related]
8. WHO's role in the global health system: what can be learned from global R&D debates?
Moon S
Public Health; 2014 Feb; 128(2):167-72. PubMed ID: 24393496
[TBL] [Abstract][Full Text] [Related]
9. Needs-driven versus market-driven pharmaceutical innovation: the consortium for the development of a new medicine against malaria in Brazil.
Kameda K
Dev World Bioeth; 2014 Aug; 14(2):101-8. PubMed ID: 24761744
[TBL] [Abstract][Full Text] [Related]
10. Stimulating research and development of pharmaceutical products for neglected diseases.
Stirner B
Eur J Health Law; 2008 Dec; 15(4):391-409. PubMed ID: 19180979
[TBL] [Abstract][Full Text] [Related]
11. [Industry, Academia and Government Partnership through the Global Health Innovative Technology Fund (GHIT)].
Hinoshita E
Yakugaku Zasshi; 2016; 136(2):237-42. PubMed ID: 26831799
[TBL] [Abstract][Full Text] [Related]
12. The importance of patent sharing in neglected disease drug discovery.
Edlin C
Future Med Chem; 2011 Sep; 3(11):1331-4. PubMed ID: 21879838
[No Abstract] [Full Text] [Related]
13. Registering medicines for low-income countries: how suitable are the stringent review procedures of the World Health Organisation, the US Food and Drug Administration and the European Medicines Agency?
Doua JY; Van Geertruyden JP
Trop Med Int Health; 2014 Jan; 19(1):23-36. PubMed ID: 24134396
[TBL] [Abstract][Full Text] [Related]
14. The right to health and medicines: the case of recent multilateral negotiations on public health, innovation and intellectual property.
Velasquez G
Dev World Bioeth; 2014 Aug; 14(2):67-74. PubMed ID: 24813066
[TBL] [Abstract][Full Text] [Related]
15. Global pharmaceutical development and access: critical issues of ethics and equity.
Lage A
MEDICC Rev; 2011 Jul; 13(3):16-22. PubMed ID: 21778954
[TBL] [Abstract][Full Text] [Related]
16. Has the implementation of the TRIPS Agreement in Latin America and the Caribbean produced intellectual property legislation that favours public health?
Oliveira MA; Bermudez JA; Chaves GC; Velásquez G
Bull World Health Organ; 2004 Nov; 82(11):815-21. PubMed ID: 15640916
[TBL] [Abstract][Full Text] [Related]
17. Trade, TRIPS, and pharmaceuticals.
Smith RD; Correa C; Oh C
Lancet; 2009 Feb; 373(9664):684-91. PubMed ID: 19167054
[TBL] [Abstract][Full Text] [Related]
18. Benchmarking progress in tackling the challenges of intellectual property, and access to medicines in developing countries.
Musungu SF
Bull World Health Organ; 2006 May; 84(5):366-70. PubMed ID: 16710545
[TBL] [Abstract][Full Text] [Related]
19. UK Commission concludes international patent laws hinder access to medicines in developing countries.
Elliott R
Can HIV AIDS Policy Law Rev; 2002 Dec; 7(2-3):59. PubMed ID: 14740605
[TBL] [Abstract][Full Text] [Related]
20. [Essential medicines and the TRIPS Agreement: collision between the right to health and intellectual property rights].
Allard Soto R
Salud Colect; 2015 Mar; 11(1):9-21. PubMed ID: 25853827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
